Insider Buying: Shattuck Labs, Inc. (NASDAQ:STTK) CEO Purchases 14,400 Shares of Stock

Shattuck Labs, Inc. (NASDAQ:STTK) CEO Taylor Schreiber acquired 14,400 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was acquired at an average price of $3.47 per share, for a total transaction of $49,968.00. Following the completion of the acquisition, the chief executive officer now directly owns 34,502 shares of the company’s stock, valued at $119,721.94. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Shattuck Labs Price Performance

STTK traded up $0.23 during mid-day trading on Wednesday, hitting $3.79. The stock had a trading volume of 546,779 shares, compared to its average volume of 361,856. The stock’s fifty day simple moving average is $8.07 and its 200-day simple moving average is $8.42. The firm has a market capitalization of $180.21 million, a price-to-earnings ratio of -1.75 and a beta of 1.85. Shattuck Labs, Inc. has a 1-year low of $1.33 and a 1-year high of $11.76.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, May 2nd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.08. Shattuck Labs had a negative net margin of 3,133.63% and a negative return on equity of 64.85%. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.30 million. Shattuck Labs’s revenue for the quarter was up 2200.0% on a year-over-year basis. As a group, research analysts expect that Shattuck Labs, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on STTK shares. Citigroup cut their price objective on shares of Shattuck Labs from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, June 17th. HC Wainwright cut their price objective on shares of Shattuck Labs from $28.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, June 20th. Needham & Company LLC cut their price objective on shares of Shattuck Labs from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, June 14th. Finally, BTIG Research lowered shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a report on Monday, June 17th.

Institutional Investors Weigh In On Shattuck Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in STTK. Vanguard Group Inc. grew its position in Shattuck Labs by 38.2% in the first quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock valued at $16,270,000 after purchasing an additional 502,860 shares in the last quarter. Franklin Resources Inc. bought a new position in shares of Shattuck Labs in the 4th quarter valued at about $11,663,000. Pinnacle Associates Ltd. grew its position in shares of Shattuck Labs by 13.9% in the 1st quarter. Pinnacle Associates Ltd. now owns 521,246 shares of the company’s stock valued at $4,660,000 after acquiring an additional 63,800 shares during the period. Monashee Investment Management LLC bought a new position in shares of Shattuck Labs in the 4th quarter valued at about $713,000. Finally, SG Americas Securities LLC grew its position in shares of Shattuck Labs by 4.8% in the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock valued at $352,000 after acquiring an additional 1,788 shares during the period. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.